Search

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Abstract & Clinical Case Submission

Abstract submission is an important part of the 7th European CAR T-cell Meeting.

Read more

Chairs and Members

ChairGiancarlo Castaman, University of Florence - Careggi University Hospital, Florence (Italy)

Co-chairAnna Falanga, University of Milan Bicocca and Hospital Papa Giovanni XXIII, Bergamo (Italy)

SWG Steering Committee
Ajay K Kakkar, Thrombosis Research Institute, London (United Kingdom)
Augusto Federici, University of Milan, University Hospital Luigi…

Read more

Aging and Hematology

The SWG "Aging and Hematology" has four main goals for the next four years (2019-2023):

To share clinically useful tools in assessing frailty and comorbidities in older adults with hematologic malignancies.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Chairs and Members

Chair and affiliation:
Willem E.

Read more

A journey to hematology – a dream come true

YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true

by Dr.

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more